Ohm wrote: Leronlimab was associated with a 40
Post# of 148175
Quote:
Leronlimab was associated with a 400%-660% increase in mPFS / PFS and a 570%-980% increase in mOS /12-month OS...
As a comparison Trodelvy (sacituzumab govitecan) had a 57% PFS and a 49% OS.
Wow! Leron can really Sac It Tu zu sacituzumab!
(If anyone gets this joke, please call your therapist right away. You have a problem.)